1. Life Sciences

USPTO Signals Strong Support for Patent Eligibility in Cutting-Edge Technologies – Duane Morris Life Sciences Law

Written by Posted on Less than 0 min read




The USPTO’s new director has singled out AI, distributed ledger technologies and diagnostics as prime areas of innovation that merit patent protection. Companies, investors and other stakeholders are closely watching how the USPTO’s active guidance may better align patent practice with the ingenuity and societal benefits these technologies represent. 

Read the full story on the Duane Morris LLP website.



Member since

More from Duane Morris

  1. Life Sciences

Neighborhood Pharmacists Demand CMS Take Enforcement Motion Towards PBMs – Duane Morris Life Sciences Legislation

As information surfaced on February 27 that Congress is punting long-debated pharmacy profit supervisor reforms, the neighborhood pharmacy foyer demanded CMS instantly take enforcement motion in opposition to improper PBM practices that the foyer says may trigger almost a 3rd of impartial pharmacies to shutter this yr. […] Jonathan Swichar, associate […]
Written by
  1. Life Sciences

Obviousness-Type Double Patenting Immunity for First-Filed, First-Issued and Later-Expiring Patent in a Family – Duane Morris Life Sciences Law

Recently, the relationship and intersection between obviousness-type double patenting (ODP) and any awarded Patent Term Adjustment (PTA) and/or Patent Term Extension (PTE) has received significant attention. The United States Court of Appeals for the Federal Circuit held in In re Cellect, 81 F.4th 1216 (Fed. Cir. 2023), that PTA and PTE, being codified […]
Written by
  1. Life Sciences

Boston Partner Daniel Pierce Interviews Treventis CEO Chris Barden – Duane Morris Life Sciences Law

Daniel R. Pierce, Corporate and IP partner in the Boston office, recently spoke with Chris Barden, CEO of firm client Treventis, about his background, his company’s research into misfolded proteins to develop cures for central nervous system diseases like Alzheimer’s, as well as Chris’ thoughts and experience at the BIO Conference. Can you tell us […]
Written by
  1. Life Sciences

FDA Issues Draft Guidance Q&A on Developing Potential Cellular and Gene Therapy Products – Duane Morris Life Sciences Law

In November 2024, the U.S. Food and Drug Administration (FDA) issued draft Guidance responding to frequently asked questions about developing cellular and gene therapy (CGT) products. This draft Guidance supplements existing finalized and draft Guidance on CGT products. Read the full Alert on the Duane Morris LLP Website. Duane Morris Member since […]
Written by
  1. Life Sciences

Federal Trade Commission Poised to File Suit Against Pharmacy Benefit Managers Based on Unlawful Medication Pricing – Duane Morris Life Sciences Law

On July 10, 2024, multiple media sources reported that the Federal Trade Commission intends to file suit against the nation’s three largest pharmacy benefit managers over​ allegations of improper pricing in connection with their negotiations with drug manufacturers that dramatically increased prices for consumers and lined the PBMs’ pockets with lucrative […]
Written by
  1. Life Sciences

Cybersecurity and Data Privacy Concerns for Wearables – Duane Morris Life Sciences Law

Duane Morris Life Sciences Law For Life Sciences innovators, challenges can be scientific, technical, business-related or legal, and Duane Morris’ lawyers share their insight into all these areas, from startup and financing, to licensing, IP, regulatory, litigation and more. Duane Morris Member since October 19, 2023 Loading + Follow Following
Written by
  1. Life Sciences

Commerce Department Singles Out Harvard for Bayh-Dole March-In Rights Enforcement – Duane Morris Life Sciences Law

There has been much concern and discussion about Commerce Secretary Howard Lutnick’s recent letter to Harvard University indicating the U.S. government’s exercise of its “march-in rights” for government-funded research resulting in IP owned by Harvard under the Bayh-Dole Act. Under the Bayh-Dole Act, recipients of U.S. government research contracts can own […]
Written by
  1. Life Sciences

Doing No Harm but Exporting Without Appropriate License Can Violate Regulations – Duane Morris Life Sciences Law

By Brandon A. Chan, Ph.D., and Brian Goldstein On June 24, 2024, the Department of Commerce’s Bureau of Industry and Service (BIS) imposed an administrative penalty on Indiana University (IU) as part of a settlement agreement following IU’s discovery and self-disclosure to BIS that its Bloomington Drosophila Stock Center engaged in the export of materials […]
Written by
  1. Life Sciences

FDA Confirms No Asbestos in Beauty Talc Merchandise for a Third 12 months in 2023 – Duane Morris Life Sciences Legislation

On April 5, 2024, the U.S. Meals and Drug Administration (FDA) confirmed that its third-party testing of beauty talc merchandise for 2023 recognized no traces of asbestos in any of the 50 beauty samples examined. FDA’s 2023 outcomes, which had been reported in a Cosmetics Constituent Replace, are per its testing for 2022 and 2021, which […]
Written by
  1. Life Sciences

FTC Voices Help for March-In Rights on Patents to Assist Management Drug Costs – Duane Morris Life Sciences Legislation

The Federal Commerce Fee (FTC) has introduced its help of the federal authorities’s use of “march-in rights” as a mechanism to regulate the worth of prescription drugs. The Nationwide Institute of Requirements and Know-how (NIST) late final yr issued its “Draft Interagency Steerage Framework for Contemplating the Train of March-In Rights” that might […]
Written by
  1. Life Sciences

Product Liability and IP Strategies for Wearables – Duane Morris Life Sciences Law

Duane Morris Life Sciences Law For Life Sciences innovators, challenges can be scientific, technical, business-related or legal, and Duane Morris’ lawyers share their insight into all these areas, from startup and financing, to licensing, IP, regulatory, litigation and more. Duane Morris Member since October 19, 2023 Loading + Follow Following
Written by
  1. Life Sciences

The Changing Beauty Regulatory Landscape – Duane Morris Life Sciences Law

Duane Morris attorney Kelly Bonner was quoted in an article in WWD on June 25, 2024. “A big deadline in the beauty and personal care regulatory landscape is fast approaching, with much more to come — although some experts believe this still isn’t enough. Under the Modernization of Cosmetics Regulation Act, or MoCRA, passed […]
Written by
  1. Life Sciences

Federal Court Grants EPA Request to Stay Litigation Challenging 2024 Ethylene Oxide Regulation Pending Agency’s Reconsideration

By Sharon L. Caffrey, Jeffrey S. Pollack and Coleen W. Hill In June 2024, industry and environmentalist parties filed a petition in the U.S. Court of Appeals for the District of Columbia Circuit for review of a national emission standards for hazardous air pollutants regulation applicable to commercial sterilization facilities, which was […]
Written by
  1. Life Sciences

FDA’s Second Warning Letter of the Year Deals with Potentially Misleading Efficacy Claims About Inhaler – Duane Morris Life Sciences Law

On August 15, 2023, the U.S. Food and Drug Administration (FDA) published a warning letter to AstraZeneca Pharmaceuticals LP, alleging that a professional sales brochure for its Breztri Aerosphere (budesonide, glycopyrrolate and formoterol fumarate) inhalation aerosol contained false or misleading claims regarding the drug’s efficacy. In view of the warning letter—only the second of […]
Written by
MoCRA featured on the Class Action Weekly Wire Podcast with Guest Kelly Bonner – Duane Morris Life Sciences Law
  1. Life Sciences

MoCRA featured on the Class Action Weekly Wire Podcast with Guest Kelly Bonner – Duane Morris Life Sciences Law

In Episode 35 of the  Class Action Weekly Wire podcast,  host Jerry Maatman interviews Duane Morris associate Kelly Bonner about the Modernization of Cosmetics  Regulation Act (MoCRA). Watch the episode below: CategoriesGeneral Tagsclass action, Kelly Bonner, MoCRA Duane Morris Member since October 19, 2023 Loading + Follow […]
Written by
  1. Life Sciences

Take Care When Paying Volume-Based Compensation to Sales Agents to Avoid Anti-Kickback Statute Violations – Duane Morris Life Sciences Law

By  Frederick R. Ball, Coleen W. Hill and Victoria (Tori) Hawekotte Pharmaceutical companies sometimes compensate sales agents per volume sold. The Fifth and Seventh Circuits have indicated that a company may structure such arrangements without running afoul of the Anti-Kickback Statute (AKS). However, such arrangements carry risk of violating the AKS and should […]
Written by
  1. Life Sciences

What Spas Need to Know – Duane Morris Life Sciences Law

The global market for intimate wellness products is expected to grow to $81.4 billion by 2028, up from $51.9 billion in 2021, according to recent market research reports. Once taboo, or the topic of hush-hush conversations, intimate wellness brands are increasingly crossing over into mainstream wellness marketing, collaborating with well-known fashion […]
Written by
  1. Life Sciences

FTC Targets Private Equity in Challenge to Anesthesiology Roll-Ups – Duane Morris Life Sciences Law

On September 21, 2023, the Federal Trade Commission sued U.S. Anesthesia Partners Inc. and Welsh, Carson, Anderson & Stowe XI L.P., among other private equity funds, in the United States District Court for the Southern District of Texas under the antitrust laws. Specifically, FTC alleges that the defendants engaged in an […]
Written by
  1. Life Sciences

Cybersecurity and Data Privacy Concerns for Wearables – Duane Morris Life Sciences Law

Duane Morris will host the second session of its Wearables Webinar Series, Cybersecurity and Data Privacy Concerns for Wearables, on Tuesday, October 21, 2025, from 12:00 p.m. to 12:30 p.m. Eastern. REGISTER About the Program The growing popularity of wearable devices that track consumers’ everyday health has been good for business. It […]
Written by
  1. Life Sciences

FDA’s Final Guidance on Decentralized Clinical Trials Published – Duane Morris Life Sciences Law

On September 18, 2024, the U.S. Food and Drug Administration (FDA) issued final Guidance on recommendations for conducting decentralized clinical trials (DCTs) for drugs, devices or biological products. Instead of using traditional clinical trial sites, DCTs hold some or all trial activities remotely at locations convenient for trial participants by, for example, using […]
Written by
Next
No Comments
Leave a comment Cancel
Comments to: USPTO Signals Strong Support for Patent Eligibility in Cutting-Edge Technologies – Duane Morris Life Sciences Law

Login

Welcome to Life Science News!
"Explore the Latest Discoveries and Breakthroughs in Life Science with Life Science News!"
Read Smart, Save Time
Pick all the topics you are interested in to fill your homepage with stories you'll love.
Join our community
Registration is closed.